ABIOMED Inc (ABMD) Stock
ABMD is no longer traded. ABIOMED was acquired by Johnson & Johnson (JNJ) on December 22, 2022.
Each ABMD share was exchanged for $380.00 in cash plus a contingent value right of up to $35.00. Prices on this page are historical; the last trade was December 21, 2022 at $381.02.
See Johnson & Johnson (JNJ) stock →ABIOMED stock price history
ABMD final trading statistics
- Final close
- $381.02
- Final trading day
- Dec 21, 2022
- Market cap at delisting
- $17.18B
- Shares outstanding
- 45.09M
- Final 52-week range
- $219.84 – $381.99
- Avg. volume (final 3 mo.)
- 1,669,337
- All-time high (split-adj.)
- $449.75 · Sep 2018
- All-time low (split-adj.)
- $1.06 · Dec 1994
- Return since IPO
- +6827.6%
- Beta
- 1.40
- Book value / share
- $34.09
- Price / book
- 11.18
ABIOMED annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $1.03B | $136.5M | $4.42 |
| FY2021 | $847.52M | $225.5M | $4.93 |
| FY2020 | $840.88M | $203.0M | $4.42 |
| FY2019 | $769.43M | $259.0M | $5.10 |
| FY2018 | $593.75M | $112.2M | $2.45 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ABIOMED Inc
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
ABIOMED stock FAQ
What happened to ABIOMED stock?
ABIOMED was acquired by Johnson & Johnson (JNJ) on December 22, 2022. Shareholders received $380.00 in cash plus a contingent value right of up to $35.00 for each share. ABMD stock stopped trading on the Nasdaq, with a final close of $381.02 on December 21, 2022.
What did ABIOMED shareholders receive?
Each ABMD share was converted into $380.00 in cash plus a contingent value right of up to $35.00. The deal was valued at about $16.6 billion.
Is ABMD stock still trading?
No. ABMD was delisted from the Nasdaq on December 22, 2022 and no longer trades on a U.S. exchange.
What was the last price of ABMD stock?
ABMD closed at $381.02 on its final trading day, December 21, 2022, for a market value of about $17.18B.
What were ABIOMED's revenue and earnings in its last full fiscal year?
ABIOMED reported revenue of $1.03B and net income of $136.5M in fiscal 2022, its last full year as a public company.
When did ABIOMED go public?
ABIOMED Inc stock began trading on July 29, 1987.